Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis S.A. (NASDAQ: CLLS) announced a partnership with Sanofi to supply alemtuzumab, an anti-CD52 monoclonal antibody, for use in Cellectis-sponsored UCART clinical trials. The CD52 knockout technology will allow UCART cells to resist alemtuzumab, enhancing T-cell persistence and expansion. Alemtuzumab will be integrated into lymphodepleting regimens for UCART22 in the BALLI-01 trial and UCART123 in the AMELI-01 trial. The agreement signifies a step toward a commercial supply relationship, aiming to drive progress in cancer therapies.
Cellectis announced key financial metrics as of April 30, 2021, revealing a total of 45,461,310 shares in capital and 51,526,159 voting rights. The company focuses on developing allogeneic CAR-T immunotherapies for cancer treatment, utilizing its proprietary gene editing technology, TALEN®. Cellectis aims to address unmet medical needs in cancers like acute myeloid leukemia and multiple myeloma, backed by over 21 years of expertise. The company is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. (NASDAQ: CLLS) announced its Q1 2021 financial results, reporting a consolidated net loss of $12 million, or $0.28 per share, compared to a net income of $20 million in Q1 2020. Consolidated revenues decreased to $28 million from $52 million, mainly due to prior upfront payments. The cash position as of March 31, 2021, stood at $231 million, extending its cash runway into 2023. Ongoing clinical trials include BALLI-01 and AMELI-01, with a new collaboration with Cytovia Therapeutics for iPSC-derived NK cells. The company anticipates presenting further clinical data by year-end.
Cellectis (Nasdaq: CLLS) announced that its upcoming general meeting on May 28, 2021, will be held in closed session due to the Covid-19 pandemic. Shareholders cannot attend physically but can vote remotely and submit questions via electronic means. The meeting will be broadcasted online. Shareholders are encouraged to use email or postal voting to participate. There are specific requirements for submitting additional agenda items or draft resolutions. Cellectis focuses on innovative CAR-T immunotherapies for various cancers and emphasizes the importance of shareholder engagement during this period.
Cellectis, a clinical-stage biopharmaceutical company, focuses on developing allogeneic CAR-T immunotherapies for cancer treatment. As of March 31, 2021, the firm reports a total of 43,039,180 shares in capital and 49,104,029 voting rights. The company aims to provide life-saving UCART product candidates to address cancers like acute myeloid leukemia and multiple myeloma. With over 21 years of expertise in gene editing, Cellectis utilizes TALEN® technology and PulseAgile electroporation to create ready-to-use gene-edited CAR T-cells.
Cellectis S.A. (NASDAQ: CLLS) has successfully completed sales of approximately $47 million in American Depositary Shares (ADS) under its ATM program initiated on March 29, 2021. A total of 2,415,630 new ADSs were issued at an average price of $19.50 each. The settlement for the new ordinary shares is expected on April 12, 2021, allowing trading on Euronext Growth and Nasdaq. This follows a shelf registration statement filed with the SEC in June 2020, which is effective for potential investors.
Cellectis S.A. (NASDAQ: CLLS) announced the filing of a prospectus supplement with the SEC related to an At-The-Market (ATM) program, allowing sales of American Depositary Shares (ADS) up to $125 million. The program aims to fund research, development, and manufacturing in the biotechnology space. Notably, this could lead to a dilution of approximately 29.74% based on existing share capital. Jefferies LLC will act as the sales agent, and the program is effective until June 2, 2023.
Cellectis, a clinical-stage biopharmaceutical company, focuses on CAR-T immunotherapies for oncology, utilizing its proprietary TALEN® gene editing technology. The company reported a total of 43,033,680 shares and 49,098,269 voting rights as of February 28, 2021. Cellectis aims to provide innovative UCART product candidates for cancers such as acute myeloid leukemia and multiple myeloma. Headquartered in Paris, Cellectis is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis reported ongoing enrollment in three Phase 1 dose-escalation trials for r/r B-ALL, r/r AML, and r/r MM, with preliminary results of the BALLI-01 study presented at ASH 2020. The company has partnered with Cytovia Therapeutics to develop TALEN® gene-edited NK cell programs and completed construction of manufacturing facilities in Paris and North Carolina. As of December 31, 2020, Cellectis had a cash position of $274 million, extending its cash runway into late 2022. A conference call is scheduled for March 5, 2021, to discuss year-end results and business updates.
Cellectis (Nasdaq: CLLS) will report its financial results for Q4 and full year 2020 on March 4, 2021, post US market close. A conference call will follow on March 5, at 8:00 AM EST. The company is developing innovative allogeneic CAR-T immunotherapies utilizing its proprietary TALEN® gene editing technology. Cellectis focuses on treating unmet needs in multiple cancers, including AML and B-ALL. The announcement comes amid ongoing advancements in its UCART product candidates and a commitment to delivering actionable therapies.
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?
How does Cellectis contribute to immuno-oncology?
